Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | MicrobiomeTrials
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
TERMINATEDPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2021-04-28Est. Completion: 2026-10-01
Enrollment target: 194 participants
Locations
University of California, Irvine, Orange, California, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
START Mountain Region, West Valley City, Utah, United States
Next Oncology Virginia, Fairfax, Virginia, United States
Institut Jules Bordet, Anderlecht, Belgium
Antwerp University Hospital, Edegem, Belgium
Clinique de l'Europe, Amiens, France
CHU Hopitaux de Bordeaux - Hôpital Saint-André, Bordeaux, France
CHU de Lyon - Louis Pradel Hospital, Bron, France
Centre Hospitalier Intercommunal de Créteil, Créteil, France
Hôpital Albert Calmette, Lille, France
L'Institut Paoli - Calmettes, Marseille, France
CHU de Nantes - Hôpital Nord Laennec, Nantes, France
Marie Wislez, Paris, France
Hôpital Bichat - Claude-Bernard, Paris, France
Hôpital Européen Georges Pompidou (HEGP), Paris, France
CHU de Poitiers, Poitiers, France
Hôpital d'Instruction des Armées Bégin, Saint-Mandé, France
Other microbiome trials you might be interested in